ANCA associated vasculitis
Clinical trials for ANCA associated vasculitis explained in plain language.
Never miss a new study
Get alerted when new ANCA associated vasculitis trials appear
Sign up with your email to follow new studies for ANCA associated vasculitis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a blood pressure pill shield blood vessels from heart attacks?
Disease control OngoingThis trial tests whether sparsentan, a tablet that blocks a chemical called endothelin and lowers blood pressure, can improve blood vessel function and reduce stiffness in people with ANCA-associated vasculitis. Vasculitis is an autoimmune disease that damages blood vessels and r…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase 2 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new drug tame vasculitis with fewer side effects?
Disease control OngoingThis study tracks the safety of avacopan, a medication for ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. Researchers will compare side effects like liver injury, heart problems, serious infections, and cancer in people taking avacopan ve…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for kids with rare blood vessel disease: avacopan trial launches
Disease control OngoingThis study tests whether the drug avacopan can help children aged 6 to 18 with a rare autoimmune disease called ANCA-associated vasculitis, which causes inflammation of blood vessels. About 20 participants will receive avacopan alongside standard treatments like rituximab or cycl…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Promising CAR-T trial for kids with rare vasculitis pulled before start
Disease control CancelledThis trial aimed to test whether anti-CD19 CAR-T cells could safely and effectively treat children with refractory ANCA-associated vasculitis, a rare autoimmune disease. The study was withdrawn before enrolling any participants, so no results are available. It was designed for ch…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kidney failure patients may ditch immune drugs in landmark trial
Disease control OngoingThis study looks at whether people with ANCA vasculitis who have reached end-stage kidney disease can safely stop taking immunosuppressive medications. The goal is to see if stopping these drugs lowers the risk of serious infections and other side effects without causing dangerou…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase 3 • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could CAR-T cells tame autoimmune diseases? early trial begins
Disease control PausedThis early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …
Matched conditions: ANCA ASSOCIATED VASCULITIS
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control CancelledThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New blood test could spot autoimmune diseases earlier
Knowledge-focused By invitation onlyThis study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC